(R)-(-)-2-propyloctanoic acid
データを補完しています。しばらくしてからページを更新すると最新の内容を表示できます
185517-21-9CCCCCC[C@@H](CCC)C(=O)OYCYMCMYLORLIJX-SNVBAGLBSA-NArundic acid has been investigated for the treatment of Amyotrophic Lateral Sclerosis (ALS).
185517-21-9DTXSID5048841CHEMBL3187683化学的特性Clear Colorless Oil
安全情報は参考情報です。供給元の安全データシート(SDS)、適用法令、専門家による評価に代わるものではありません。
ONO-256 is a neuroprotective because of its actions on glia cells. It has inhibitory effects on the synthesis of a calcium-binding protein S100B. ONO-2506 is undergoing clinical trials for the treatment of patients with stroke and Alzheimer's disease.
説明Arundic acid is an inhibitor of astrocyte activation. It reduces increases in brain glial fibrillary acid protein (GFAP) and S100β levels, markers of astrocyte activation, in a rat model of permanent focal ischemia induced by middle cerebral artery occlusion when administered at a dose of 10 mg/kg. Arundic acid (3 and 10 mg/kg) decreases the number of TUNEL-positive neurons, reduces infarct size, and improves motor performance in the rotarod test in the same model. It also reduces descent time and time to turn in a pole test, indicating reversal of motor deficits, in a mouse model of MPTP-induced Parkinson''s disease when administered at a dose of 30 mg/kg.
使用An astrocyte modulating agent, in acute ischemic stroke.